These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

245 related items for PubMed ID: 30144048

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein.
    Wood MD, Gillard M.
    Epilepsia; 2017 Feb; 58(2):255-262. PubMed ID: 28012162
    [Abstract] [Full Text] [Related]

  • 3. Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment.
    Klitgaard H, Matagne A, Nicolas JM, Gillard M, Lamberty Y, De Ryck M, Kaminski RM, Leclercq K, Niespodziany I, Wolff C, Wood M, Hannestad J, Kervyn S, Kenda B.
    Epilepsia; 2016 Apr; 57(4):538-48. PubMed ID: 26920914
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Favorable adverse effect profile of brivaracetam vs levetiracetam in a preclinical model.
    Sanon NT, Gagné J, Wolf DC, Aboulamer S, Bosoi CM, Simard A, Messiet E, Desgent S, Carmant L.
    Epilepsy Behav; 2018 Feb; 79():117-125. PubMed ID: 29287214
    [Abstract] [Full Text] [Related]

  • 10. Brivaracetam efficacy and safety in focal epilepsy.
    Makke Y, Abou-Khalil B.
    Expert Rev Neurother; 2019 Oct; 19(10):955-964. PubMed ID: 31195850
    [Abstract] [Full Text] [Related]

  • 11. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.
    Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, Fuks B.
    Proc Natl Acad Sci U S A; 2004 Jun 29; 101(26):9861-6. PubMed ID: 15210974
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Interaction of Approved Drugs with Synaptic Vesicle Protein 2A.
    Danish A, Namasivayam V, Schiedel AC, Müller CE.
    Arch Pharm (Weinheim); 2017 Apr 29; 350(3-4):. PubMed ID: 28220535
    [Abstract] [Full Text] [Related]

  • 16. Brivaracetam Prevents the Over-expression of Synaptic Vesicle Protein 2A and Rescues the Deficits of Hippocampal Long-term Potentiation In Vivo in Chronic Temporal Lobe Epilepsy Rats.
    Ge YX, Lin YY, Bi QQ, Chen YJ.
    Curr Neurovasc Res; 2020 Apr 29; 17(4):354-360. PubMed ID: 32407277
    [Abstract] [Full Text] [Related]

  • 17. Modulation of the conformational state of the SV2A protein by an allosteric mechanism as evidenced by ligand binding assays.
    Daniels V, Wood M, Leclercq K, Kaminski RM, Gillard M.
    Br J Pharmacol; 2013 Jul 29; 169(5):1091-101. PubMed ID: 23530581
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Brivaracetam for the treatment of epilepsy.
    Schulze-Bonhage A.
    Expert Opin Pharmacother; 2011 Aug 29; 12(12):1959-66. PubMed ID: 21682662
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.